Salud financiera de hoja de balance de Merck

Salud financiera controles de criterios 4/6

Merck tiene un patrimonio de accionistas total de $37.6B y una deuda total de $35.1B, lo que sitúa su ratio deuda-patrimonio en 93.1%. Sus activos y pasivos totales son $106.7B y $69.0B respectivamente. El BAIT de Merck es de $6.5B, por lo que su ratio de cobertura de intereses es de 8.3. Tiene efectivo e inversiones a corto plazo que ascienden a $7.1B.

Información clave

84.7%

Ratio deuda-patrimonio

US$34.22b

Deuda

Ratio de cobertura de intereses	7.6x
Efectivo	US$5.62b
Patrimonio	US$40.42b
Total pasivo	US$65.43b
Activos totales	US$105.85b

Actualizaciones recientes sobre salud financiera

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Apr 09

Recent updates

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

Dec 25

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($32.2B) de MRK superan a sus pasivos a corto plazo ($25.7B).

Pasivo a largo plazo: Los activos a corto plazo ($32.2B) de MRK no cubren sus pasivos a largo plazo ($43.3B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de MRK (74.3%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de MRK ha pasado de 93.8% a 84.7% en los últimos 5 años.

Cobertura de la deuda: La deuda de MRK está bien cubierta por el flujo de caja operativo (37.1%).

Cobertura de intereses: Los pagos de intereses de la deuda de MRK están bien cubiertos por el BAIT (8.3x cobertura).

Salud financiera de hoja de balance de Merck

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Recent updates

Insider exercised options to buy US$1.8m worth of stock.

Merck Q1: There's Still Room For Growth

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck's Future Brightens With Winrevair's Blockbuster Potential

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck: A High-Conviction Investment For Long-Term Growth

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Insider notifies of intention to sell stock

Insider exercised options and sold US$1.7m worth of stock

Executive VP & General Counsel recently sold US$3.8m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 16%

Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Third quarter dividend of US$0.77 announced

Is Merck & Co., Inc. (NYSE:MRK) Trading At A 47% Discount?

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera